reason report
rais estim price target anoth impress
bottom line afternoon pre-announc outstand
includ ingrezza sale versu consensu
estim result rais
product sale estim -- solid print even
impress per math consid fact price per
script drop sequenti compani work convert
patient capsul three strong quarter
surpass consensu estim continu
earli trajectori launch remain support larg tardiv
dyskinesia market opportun turn increas
sale project price target estim script
written versu written indic
work convert franchis toward
capsul price per script drop reduct
expect price continu repres headwind
model sequenti drop upon addit realiz
convers steadi price thereaft impress print
underli view current ingrezza consensu
far low increas revenu estim along
impli margin expans new price target also
expect profit basi also
announc retir longtim discuss
ingrezza sale beat sell side consensu
impress broadli even context recent stock run
consid sequenti price drop entranc teva
td market approv austedo new free drug program
initi believ investor expect net sale
modestli instead pre-report reflect
sequenti product sale growth would sequenti
growth price per script remain flat report sale
script total appear much convers capsul
much cheaper two capsul occur back
half quarter confirm dynam follow-up
call thu updat number account addit price
headwind new product sale estim
well current consensu also increas sale
lower expens estim
togeth respons increas price target
maintain ingrezza sale estim one
hardest thing understand launch degre earli
methodolog dcf analysi termin growth
net debt total capit
per share net cash per dilut share
outstand includ options/warr
compani inform leerink partner llc research
revenu mm ep
pleas refer page analyst certif import disclosur price chart disclosur specif
